Abstract
Carcinoma of the rectum, a common malignancy in developed countries, accounts for approximately one third of colorectal cancers. Although majority of the localized rectal cancers are potentially curable, local recurrence remains a serious problem with severe disability and impaired quality of life. Rectal cancer, which was a surgically-managed tumour, now requires the coordinated efforts of multidisciplinary team, colorectal surgery, radiation oncology, medical oncology, radiology and others. In addition to the staging workup, pre-treatment evaluation of the local disease, by endorectal ultrasound (EUS) and multislice computer tomography (CT) and magnetic resonance imaging (MRI), is utmost important to determine the surgical approach and the need for the various other treatment modalities: radiation and chemotherapy (ChT). The introduction of Total Mesorectal Excision (TME) and neoadjuvant Radiation Therapy (RT) have led to significant improvement in the loco-regional control of the rectal cancer, 90–94%. TME is now widely accepted as the standard surgical technique for rectal cancer. Local recurrence rates have been shown to decrease significantly with TME alone. However, the addition of radiation therapy has furthered this improvement, especially in patients having a circumferential resection margin (CRM) that is involved with tumour on pre-operative imaging. There are two radiation modalities used in the treatment of patients with solid tumours, external beam radiation (EBRT) and brachytherapy (BT). In rectal cancer EBRT is primarily used to optimize the rate of local control achieved by surgery. Numerous clinical trials have confirmed its benefit, with or without chemotherapy, in improving local control. However, the survival advantage and the impact on distant metastasis are controversial. In view of normal organ toxicity associated with EBRT, newer radiation delivery techniques have been explored. High dose rate brachytherapy (HDRB) delivers radiation by an endoluminal approach, avoiding the delivery through other organs, and as such, decreases normal organ toxicity. The emerging prospective data are very promising and an international phase III study is being conducted. Despite significant improvement in local control, over the last decade, one third of the patients continue to fail at distance, with metastases. The role of chemotherapy in conjunction with radiation therapy as a neo-adjuvant modality to TME has been, mostly, accepted as routine in North America. However, to date, evidence from Phase III-randomized studies in rectal cancer fails to demonstrate any benefit from additional post-operative adjuvant 5-fluorouracil (FU)-based chemotherapy in terms of disease-free or overall survival in locally advanced rectal cancer. There have been significant achievements in the treatment of rectal cancer over the past decade with multidisciplinary approach becoming the standard of care. Such approach allows for the selection of those patients who are cured with surgery alone, as well as those at risk for failing locally, thus achieving a balance between treatment toxicity risks and tumour control gains.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- APR:
-
Abdominoperineal resection
- BT:
-
Brachytherapy
- CAA:
-
Coloanal anastomosis
- CAPOX:
-
Capecitabine and oxaliplatin
- CKVO:
-
Commissie Klinisch Vergelijkend Onderzoek
- CRM:
-
Circumferential resection margin
- CTRT:
-
Chemotherapy radiotherapy
- CT:
-
Computer tomography
- ChT:
-
Chemotherapy
- DFS:
-
Disease-free survival
- EBRT:
-
External beam radiation
- EUS:
-
Endorectal ultrasound
- FOLFOX:
-
Folinic acid, oxaliplatin and fluorouracil
- FU:
-
5-Fluorouracil
- HDRB:
-
High dose rate brachytherapy
- HR:
-
Hazard ratio
- LAR:
-
Low anterior resection
- LC:
-
Laparoscopic colectomy
- LV:
-
Leucovorin
- LVI:
-
Lymphovascular invasion
- MRI:
-
Magnetic resonance imaging
- N:
-
Node
- OAS:
-
Overall survival
- RT:
-
Radiation therapy
- SPS:
-
Sphincter-preserving surgery
- T:
-
Tumour
- TAE:
-
Trans-anal excision
- TME:
-
Total mesorectal excision
- UPSO:
-
Ultra-small super paramagnetic iron oxide
References
Akasu T, Kondo H, Moriya Y et al. (2000). Endorectal ultrasonography and treatment of early stage rectal cancer. World J Surg 34: 1061–68.
Beets-Tan RG, Beets GI, Vliegen RF et al. (2001). Accuracy of magnetic resonance imaging in prediction of tumour-free resection margin in rectal cancer surgery. Lancet 357: 497–504.
Bosset JF, Collette L, Calais G et al. (2006). Chemotherapy with pre-operative radiotherapy in rectal cancer. N Engl J Med 355: 1114–23.
Brierly J, Cummings BJ, Wong WS et al. (1995). Adecarcinoma of the rectum treated with by radical external beam therapy. Int J Radiat Oncol Biol Phys 31(2) 255–59.
Brown G, Radcliffe AG, Newcombe RG et al. (2003a). Pre-operative assessment of prognostic factors in rectal cancer using high-resolution magnetic imaging. Br J Surg 90: 355–64.
Brown G, Richard CJ, Bourne MW et al. (2003b). Morphologic predictors of lymph node status in rectal cancer with the use of high-spatial resolution MR imaging with histopathological comparison. Radiology 227(2): 371–77.
Bujko K, Nowacki MP, Nasierowska-Guttmejer A et al. (2006). Long-term results of a randomized trial comparing pre-operative short-course radiotherapy with pre-operative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 93: 1215–23.
Camma C, Giunta M, Fiorica F et al. (2000). Pre-operative radiotherapy for resectable rectal cancer: A meta-analysis. J Am Med Assoc 284: 1008–15.
Canadian Cancer Statistics (2008). Toronto ISSN 0835-2976: Canadian Cancer Society/National Cancer Institute of Canada.
Chakravarti A, Compton CC, Shellito PC et al. (1999). Long-term follow-up of patients with rectal cancer managed by local excision with and without adjuvant irradiation. Ann Surg 230: 49–54.
Colorectal Cancer Collaborative Group (2001). Adjuvant radiotherapy for rectal cancer: A systematic overview of 8,507 patients from 22 randomised trials. Lancet 358: 1291-304.
Cutsem EV, Dicato M, Haustermans K et al. (2008). The diagnosis and management of rectal cancers: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal cancer, Barcelona, 2007. Ann Oncol 19(Suppl. 6): v1–6.
Enker WE, Thaler HT, Cranor ML, Polyak T (1995). Total mesorectal excision in the operative treatment of carcinoma of the rectum. J Am Coll Surg 181: 335–46.
François Y, Nemoz CJ, Beaulieux J et al. (1999). Influence of the interval between pre-operative radiation therapy and surgery on downstaging and the rate of sphincter preservation surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol 17: 2396–402.
Garcia-Aguilar J, Pollark J, Lee SH et al. (2002). Accuracy of endorectal ultrasonography in pre-operative staging of rectal tumours. Dis Colon Rectum 45: 10–15.
Gastrointestinal Tumor Study Group (1985). Prolongation of the disease free interval in surgically treated rectal carcinoma. N Engl J Med 312: 1465–72
Gerard JP, Ayzac L, Coquard R et al. (1996). Endocavitary irradiation for early rectal carcinomas T1 (T2): a series of 101 patients treated with the Papillon technique. Int J Radiat Oncol Biol Phys 36: 775–83.
Gerard JP, Chapet O, Nemoz C et al. (2004). Improved sphincter preservation in low rectal cancer with high dose pre-operative radiotherapy: the Lyon R96-02 randomized trial. J Clin Oncol 22: 2404–9.
Gerard JP, Conroy T, Bonnetain F et al. (2006). Pre-operative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 24: 4620–25.
Glimelius B, Gronberg H, Jarhult J et al. (2003). A systematic overview of radiation therapy effects in rectal cancer. Acta Oncol 42: 476–92.
Gualdi GF, Casciani E, Guadalaxara A et al. (2000). Local staging of rectal cancer with transrectal ultrasound and endorectal magnetic resonance imaging: comparaison with histologic findings. Dis Colon Rectum 43: 338–45.
Heald RJ (1998). The ‘Holy Plane’ of rectal surgery. J R Soc Med 81: 503–8
Heald RJ, Moran BJ, Ryall RD et al. (1998). Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978–1997. Arch Surg 133: 894–99.
Herbertson RA, Lee ST, Tebbutt N, Scott AM (2007). The expanding role of PET technology in the management of patients with colorectal cancer. Ann Oncol 18: 1774–81.
Horiot JC, Roth SL, Calais G et al. (1990). The Dijon clinical staging system for early rectal carcinomas amenable to intracavitary treatment techniques. Radiother Oncol 18(4): 329–337.
Hyams DM, Mamounas EP, Petrelli N et al. (1997). A clinical trial to evaluate the worth of pre-operative multimodality therapy in patients with operable carcinoma of the rectum: a progress report of the National Surgical Breast and Bowel Project Protocol R-03. Dis Colon Rectum 40: 131–39.
Kapiteijn E, Marijnen CA, Nagtegaal ID et al. (2001). Pre-operative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345: 638–46.
Koh DM, Brown G, Temple L et al. (2004). Rectal cancer: mesorectal lymph nodes at MR imaging with USPIO versus histopathologic findings–initial observations. Radiology 231: 91–99.
Krook J, Moertel C, Gunderson L et al. (1991). Effective surgical adjuvant therapy for high risk rectal carcinoma. N Engl J Med 324: 709–15.
Lee JH, Lee JH, Ahn JH et al. (2002). Randomized trial of postoperative adjuvant therapy in stage II and III rectal cancer to define the optimal sequence of chemotherapy and radiotherapy: A preliminary report. J Clin Oncol 20: 1751–58.
MacFarlane JK, Ryall RD, Heald RJ (1993). Mesorectal excision for rectal cancer. Lancet 341: 457–60.
MacKay SG, Pager CK, Joseph D et al. (2003). Assessment of the accuracy of transrectal ultrasonography in anorectal neoplasia. Br J Surg 90: 346–50.
Martling AL, Holm T, Rutqvist LE et al. (2000). Effect of a surgical training programme on outcome of rectal cancer in the County of Stockholm. Stockholm Colorectal Cancer Study Group, Basingstoke Bowel Cancer Research Project. Lancet 356: 93–96.
Mercury study group (2007). Extramural depth of tumour invasion at thin-section MR in patients with rectal cancer. Results of the Mercury study. Radiology 1: 132–39.
Mezhir JJ, Smith KD, Fichera A et al. (2005). Presence of distal intramural spread after pre-operative combined-modality therapy for adenocarcinoma of the rectum: what is now the appropriate distal resection margin? Surgery 138(4): 658–63; discussion 663–64.
Nagtegaal ID, Quirke P (2008). What is the role for the circumferential margin in the modern treatment of rectal cancer? J Clin Oncol 26: 303–12.
Nascimbeni R, Burgart LJ, Nivatvongs S et al. (2002). Risk of lymph node metastasis in T1 carcinoma of the colon and rectum. Dis Colon Rectum 45(2): 200–6.
Nash G, Weiser MR, Guillem JG et al. (2009). Long-term survival after transanal excision of T1 rectal cancer. Dis Colon Rectum 52(4): 577–82.
NIH (1990). NIH consensus conference: Adjuvant therapy for patients with colon and rectal cancer. J Am Med Assoc 264: 1444–50.
Papillon J (1982). Rectal and Anal Cancer: Conservative Treatment by Irradiation: An Alternative to Radical Surgery. Springer: New York, NY.
Peeters KC, Marijnen CA, Nagtegaal ID et al. (2007). The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 246: 693–701.
Quirke P, Durdey P, Dixon MF et al. (1986). Local recurrence of rectal adenocarcinoma due to inadequate surgical resection: Histologic study of lateral tumour spread and surgical excision. Lancet 2: 996–99.
Remzi FH, Fazio VW, Gorgun E et al. (2005). Quality of life, functional outcome, and complications of coloplasty pouch after low anterior resection. Dis Colon Rectum 48: 735–43.
Salerno GV, Daniels IR, Moran BJ et al. (2009). Magnetic resonance imaging prediction of an involved surgical resection margin in low rectal cancer. Dis Colon Rectum 52(4): 632–39.
Sauer R, Becker H, Hohenberger W et al. (2004). Pre-operative versus post-operative chemoradiotherapy for rectal cancer. N Engl J Med 351: 1731–40.
Sebag-Montefiore D, Stephens RJ, Steele R et al. (2009). Pre-operative radiotherapy versus selective post-operative chemo-radiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomized trial. Lancet 373: 811–20.
Solomon MJ, McLeoad RS (1993). Endoluminal transrectal ultrasonography: accuracy, reliability and validity. Dis Colon Rectum 36: 200–5.
Tasbas M, Sischy B (1996). Endocavitary radiation for treatment of distal rectal carcinoma and 20 years experience. Int J Radiat Oncol Biol Phys 36: 211 (abstract).
Vuong T, Devic S, Moftah B et al. (2005). High-dose-rate endorectal brachytherapy in the treatment of locally advanced rectal carcinoma: technical aspects. Brachytherapy 4: 230–35.
Wolmark N, Wieand S, Hyams D et al. (2000). Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National surgical adjuvant breast and Bowel project Protocol R-02. J Natl Canc Inst 92: 388–96.
Wong RKS, Tandan V, De Silva S, Figueredo A (2007). Pre-operative radiotherapy and curative surgery for the management of localized rectal carcinoma. In: Cochrane Database of Systematic Reviews, Issue 2. Wiley: New York, NY.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Vuong, T., Niazi, T., Liberman, S., Galiatsatos, P., Devic, S. (2010). Diagnosis and Treatment of Rectal Cancer. In: Beauchemin, N., Huot, J. (eds) Metastasis of Colorectal Cancer. Cancer Metastasis - Biology and Treatment, vol 14. Springer, Dordrecht. https://doi.org/10.1007/978-90-481-8833-8_14
Download citation
DOI: https://doi.org/10.1007/978-90-481-8833-8_14
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-90-481-8832-1
Online ISBN: 978-90-481-8833-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)